This article is more than 5 years old. Information may no longer be current.
Genentech completes enrollment in ranibizumab port delivery system trial
Click Here to Manage Email Alerts
Enrollment has been completed in Genentech’s phase 2 clinical trial of the ranibizumab port delivery system implant in patients with wet age-related macular degeneration, according to a company announcement.
The multicenter, randomized, active treatment-controlled LADDER (Long Acting Delivery of Ranibizumab) trial is evaluating the efficacy of the RPDS implant for the sustained delivery of Lucentis in patients with wet AMD who have previously responded to anti-VEGF treatment.
The trial is evaluating the implant with three different ranibizumab formulations. “The primary endpoint is the time until a patient first requires the RPDS implant to be refilled according to protocol-defined refill criteria,” the announcement said.
“We are excited to announce we have completed enrollment in the LADDER study for the RPDS, as we believe it could potentially be a useful new treatment platform for both wet AMD patients and ophthalmologists,” Giulio Barteselli, MD, Genentech Ophthalmology’s associate medical director, said in the announcement.